Company

RIBOMIC

リボミック

4591 · TSE · Pharmaceutical

Financials Company only

Revenue¥3.00m+42.4% year on yearCompany only · FY3/26

Ordinary profit−¥1.14bnCompany only · FY3/26

Revenue

¥80.9mFY3/22

¥66.0mFY3/23

—FY3/24

¥2.11mFY3/25

¥3.00mFY3/26

Ordinary profit

−¥1.64bnFY3/22

−¥1.65bnFY3/23

−¥983mFY3/24

−¥1.01bnFY3/25

−¥1.14bnFY3/26

Op. cash flow

−¥1.50bnFY3/22

−¥1.71bnFY3/23

−¥933mFY3/24

−¥997mFY3/25

−¥1.11bnFY3/26

Employees25 peopleFY3/26

Average salary¥7.09mFY3/26

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history

Five-year history
Fiscal year	Revenue	Ordinary profit	EPS	Total assets	Net assets	Op. cash flow
FY3/26	¥3.00m+42.4% year on year	−¥1,139m	−¥23.07	¥2.98bn	¥2.84bn	−¥1,111m
FY3/25	¥2.11m	−¥1,015m	−¥25.21	¥3.19bn	¥3.04bn	−¥997m
FY3/24	—	−¥983m	−¥28.70	¥3.55bn	¥3.39bn	−¥933m
FY3/23	¥65.97m−18.5% year on year	−¥1,649m	−¥53.14	¥4.58bn	¥4.38bn	−¥1,709m
FY3/22	¥80.91m	−¥1,636m	−¥59.95	¥4.95bn	¥4.69bn	−¥1,499m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100YF0X · Japan GAAP. Each figure's years come from one report's five-year summary.